Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAetna pemetrexed (Alimta) Coverage Update | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0687

    Pemetrexed (Alimta)

    Customize your policy alerts

    Sign up for Aetna Policy 0687 alerts

    Get alerted when Policy 0687 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy defining Aetna's coverage, continuation, exclusions, dosing, and coding for pemetrexed (Alimta and alternatives) for commercial medical plans.

    Policy Summary
    PayerAetna
    PolicyPemetrexed (Alimta)
    Policy CodePolicy 0687
    Change TypeNo material changes
    Effective Date07/16/2004
    Last ReviewFeb 20, 2024
    Next Review Date09/26/2024
    Key ActionObtain prior authorization and document indication, regimen, vitamin B12 and folic acid supplementation, and planned dosing schedule.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    >10FDA/compendial indications
    500 mg/m2Common dose
    CrCl ≥45Renal threshold
    ≥1500Minimum ANC
    J9305...HCPCS J-codes listed

    Coverage Criteria

    Initial Therapy

    Covered when ANY of the following indications are met:

    Covered Indications: 1. Bladder cancer — locally advanced, metastatic, or relapsed transitional cell urothelium cancer, as second-line treatment; 2. Cervical cancer — persistent, recurrent, or metastatic cervical cancer; 3. Ovarian, fallopian tube, or primary peritoneal cancer (specified histologies) — persistent or recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, carcinosarcoma (malignant mixed Mullerian tumors), clear cell carcinoma of the ovary, grade 1 endometrioid carcinoma, low-grade serous carcinoma/ovarian borderline epithelial tumor (low malignant potential), or mucinous carcinoma of the ovary, as single-agent therapy; 4. Pleural or peritoneal mesothelioma (including pericardial and tunica vaginalis testis) when pemetrexed is used as a single agent or in combination with cisplatin or carboplatin, or in combination with bevacizumab or durvalumab and a platinum agent; 5. Non-squamous non-small-cell lung cancer (NSCLC), including leptomeningeal metastases; 6. Primary central nervous system (CNS) lymphoma, as a single agent; 7. Thymomas and thymic carcinomas, as a single agent.

    See exclusions for squamous NSCLC

    Continuation Therapy

    Continuation of Therapy:

    Coding

    Other related CPT codesCPT
    96365
    96366
    96367
    96368
    96379
    96409
    96411
    96413
    96415
    96416
    1–10 of 11
    1/2
    HCPCS codes covered if selection criteria are metHCPCSCovered
    J9305Injection, pemetrexed, 10 mg.
    J9294Injection, pemetrexed (hospira) not therapeutically equivalent to j9305, 10 mg.
    J9296Injection, pemetrexed (accord) not therapeutically equivalent to j9305, 10 mg.
    J9297Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg.
    J9314Injection, pemetrexed (teva) not therapeutically equivalent to J9305, 10 mg.
    J9322Injection, pemetrexed (bluepoint) not therapeutically equivalent to j9305, 10 mg.
    J9323Injection, pemetrexed ditromethamine, 10 mg.
    J9324Injection, pemetrexed (pemrydi rtu), 10 mg.
    J9035Injection, bevacizumab, 10 mg.
    J9045Injection, carboplatin, 50 mg.
    1–10 of 12
    1/2
    ICD-10 codes covered if selection criteria are metICD-10Covered
    C33 - C34.92Malignant neoplasm of trachea, bronchus and lung [non-small-cell lung cancer (NSCLC) only- not small cell lung cancer] [covered for non squamous cell non-small cell lung cancer only].
    C37Malignant neoplasm of thymus [thymic carcinoma].
    C38.4Malignant neoplasm of pleura.
    C45.0Mesothelioma of pleura.
    C45.1Mesothelioma of peritoneum [persistent or recurrent].
    C45.2Mesothelioma of pericardium.
    C45.7Mesothelioma of other sites [tunica vaginalis testis mesothelioma].
    C45.9Mesothelioma, unspecified.
    C48.2Malignant neoplasm of peritoneum, unspecified [primary peritoneal cancer].
    C53.0 - C53.9Malignant neoplasm of cervix uteri.
    1–10 of 13
    1/2

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization required for pemetrexed (J-code billed under commercial medical plans). Prior authorization should indicate the requested indication, regimen, and supporting documentation; pemetrexed is covered only for specified indications in this policy and is excluded for squamous NSCLC.

    • Document indication (diagnosis code and stage)
    • Submit prior regimen details and prior chemotherapy status where applicable
    • Include planned regimen and dosing (e.g., pemetrexed 500 mg/m2 with cisplatin 75 mg/m2 for mesothelioma)
    Prior Authorization

    Mesothelioma Regimen — Prior Authorization Details

    For pleural or peritoneal mesothelioma, prior authorization should reflect the standard mesothelioma regimen when applicable (for example, pemetrexed 500 mg/m2 IV on Day 1 of each 21‑day cycle in combination with cisplatin 75 mg/m2 IV) and must document that pemetrexed will be used as single agent or in combination with platinum agents or with bevacizumab/durvalumab plus platinum as allowed by the policy.

    Covered Regimens and Dosing

    inv-62: first-line

    First-line NSCLC: Pemetrexed 500 mg/m2 IV on Day 1 every 21 days as part of first-line therapy for metastatic or locally advanced non‑squamous NSCLC (single agent or in combination with pembrolizumab and platinum; contraindicated in squamous histology and requires creatinine clearance ≥45 mL/min).CrCl ≥ 45 mL/min

    Dosing and renal threshold per labeled guidance

    inv-63: first-line

    First-line mesothelioma: Pemetrexed 500 mg/m2 IV Day 1 every 21 days in combination with cisplatin 75 mg/m2 IV Day 1 for malignant pleural mesothelioma; folic acid and vitamin B12 supplementation and corticosteroid prophylaxis per prescribing information.

    FDA‑approved regimen for pleural mesothelioma

    inv-64: salvage

    Biomarker Requirements

    EGFR or ALK
    EGFR/ALK requirementNo EGFR or ALK genomic tumor aberrations for use in combination with pembrolizumab and platinum chemotherapy
    ContextApplies to initial treatment of metastatic non-squamous NSCLC in combination with pembrolizumab and platinum
    Provider actionConfirm tumor genomic testing for EGFR and ALK prior to initiating combination regimen
    EGFR mutation; MTHFR 677 C>T
    EGFR mutation contextEGFR-mutant NSCLC patients with leptomeningeal metastasis had longer post-LM survival when pemetrexed was used after LM
    MTHFR 677 C>TMeta-analysis found MTHFR 677 C>T does not predict pemetrexed effectiveness for PFS/OS, but the T allele may increase hematologic toxicity

    Definitions and Prescribing Notes

    Pemetrexed (Alimta) is a multitargeted antifolate approved by the FDA for non‑squamous non‑small cell lung cancer (NSCLC) and for use in combination with cisplatin for unresectable malignant pleural mesothelioma; it is also used compendially for a variety of other malignancies. Labeling and the policy require folic acid and vitamin B12 supplementation and corticosteroid prophylaxis to reduce toxicity, and dosing commonly cited is 500 mg/m2 IV on Day 1 of each 21‑day cycle.

    Pemetrexed mechanism (overview)
    Mechanism of actionAlimta (pemetrexed) is a pyrimidine-based folate analog that inhibits multiple enzymes in folate metabolism and DNA synthesis
    Clinical relevanceMultitargeted antifolate activity may overcome resistance to agents targeting single folate enzymes
    Indications linkMechanism supports use in multiple solid tumors including NSCLC and mesothelioma per compendial references
    Supportive supplementation

    Line of Therapy Mapping

    inv-62: first-line

    First-line NSCLC dosing: Pemetrexed 500 mg/m2 IV Q21 days as single agent or with pembrolizumab and platinum; maintenance dosing until progression or unacceptable toxicity; ensure creatinine clearance ≥45 mL/min prior to administration.CrCl ≥ 45 mL/min

    Per dosing and administration guidance

    inv-63: first-line

    First-line mesothelioma dosing: Pemetrexed 500 mg/m2 IV Q21 days in combination with cisplatin 75 mg/m2 IV Q21 days; folic acid and vitamin B12 supplementation and corticosteroid prophylaxis required per labeling.

    FDA‑approved regimen

    inv-64: salvage

    Revision History

    2024-02-20last_review

    Policy was last reviewed on 02/20/2024.

    2004-07-16effective

    Policy became effective on 07/16/2004.

    2024-09-26next_reviewLatest

    Next scheduled policy review is 09/26/2024.

    Policy Summary
    PayerAetna
    PolicyPemetrexed (Alimta)
    Policy CodePolicy 0687
    Change TypeNo material changes
    Effective Date07/16/2004
    Last ReviewFeb 20, 2024
    Next Review Date09/26/2024
    Key ActionObtain prior authorization and document indication, regimen, vitamin B12 and folic acid supplementation, and planned dosing schedule.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and DocumentationCovered Regimens and DosingBiomarker RequirementsDefinitions and Prescribing NotesLine of Therapy MappingRevision History
    Continuation is medically necessary when the member has an indication listed in the policy and there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

    Initial therapy — malignant pleural mesothelioma

    Covered when ALL of the following are met (standard mesothelioma regimen):

    Mesothelioma combination therapy: Pemetrexed 500 mg/m2 IV on Day 1 of each 21-day cycle in combination with cisplatin 75 mg/m2 IV on Day 1, with folic acid and vitamin B12 supplementation and corticosteroid prophylaxis as per prescribing information.

    FDA‑approved regimen and dosing for malignant pleural mesothelioma

    Malignant peritoneal mesothelioma

    Covered when ALL of the following are met (peritoneal mesothelioma / re-challenge context):

    Malignant peritoneal mesothelioma: Pemetrexed plus cisplatin systemic therapy may be used in first-line or re-challenge settings when patient performance status and general health permit; pemetrexed monotherapy has been used following CRS/HIPEC and pemetrexed re-challenge (with or without cisplatin) has reported disease control and prolonged survival in select cases.

    Evidence from case reports and small series; UpToDate notes pemetrexed+carboplatin may be preferred in palliative setting for less toxicity

    Maintenance therapy — Non-Small Cell Lung Cancer

    Maintenance pemetrexed is supported when ALL of the following are met:

    Maintenance pemetrexed criteria: 1) Histologically or cytologically confirmed locally advanced or metastatic non-squamous NSCLC; 2) Disease has not progressed after 4 cycles of platinum-based first-line chemotherapy; 3) Patient has ECOG performance status 0-2 and adequate bone marrow, renal, and hepatic function; 4) Concomitant supplementation with folic acid and vitamin B12 initiated and corticosteroid prophylaxis administered per labeling; 5) Dosing consistent with FDA labeling (500 mg/m2 IV on Day 1 of each 21-day cycle).

    Based on FDA approval and randomized trial evidence showing improved PFS and OS in non-squamous histology

    First-line combination therapy — NSCLC

    Pemetrexed in combination with platinum agents for NSCLC — considerations:

    First-line pemetrexed+cisplatin: Use in first-line combination with cisplatin is indicated for non-squamous NSCLC; dosing: pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV every 21 days. Evidence includes randomized trials with histology‑specific benefit favoring non-squamous tumors.

    Phase III data; see prescribing information for dosing and administration

    Mesothelioma (peritoneal) — investigational/limited evidence

    Pemetrexed in malignant peritoneal mesothelioma (DMPM):

    DMPM pemetrexed use: Case reports and small series report activity of pemetrexed alone or with cisplatin, including pemetrexed re‑challenge, with reported disease control and prolonged survival in select patients; evidence is limited and primarily from small cohorts and case reports.

    Investigational/limited evidence; UpToDate and small series cited

    Small-cell lung cancer — Not recommended

    Small cell lung cancer:

    SCLC pemetrexed: Pemetrexed plus carboplatin was shown to be inferior to etoposide‑carboplatin for extensive‑stage small‑cell lung cancer (ES‑SCLC) in a phase III trial and thus is not recommended as standard therapy for ES‑SCLC.

    Evidence shows worse OS, PFS, and response rates versus standard etoposide‑carboplatin

    Thymic malignancies — Second-line option

    Thymic malignancies:

    Thymoma/thymic carcinoma: NCCN recommends pemetrexed (with or without prednisone) as a second-line systemic therapy option for thymic malignancies; panel members favor pemetrexed and paclitaxel for thymomas.

    Guideline‑based recommendation (NCCN)

    Evidence-based coverage conclusions and required precautions

    Clinical conclusions and implications drawn from cited studies:

    Bevacizumab plus pemetrexed-platinum: Multiple analyses including a Bayesian network meta‑analysis found no consistent efficacy advantage to adding bevacizumab to pemetrexed‑platinum; authors concluded routine addition is unjustified based on available RCT data.

    Zhao et al. Bayesian NMA

    Real-world evidence for carboplatin/pemetrexed + bevacizumab: A retrospective cohort (n=4,724) observed improved median overall survival with addition of bevacizumab to carboplatin/pemetrexed (12.1 vs 8.6 months; HR 0.80), but authors cautioned about potential unmeasured confounding and missing performance status data.

    Bagley et al. real‑world study

    Elderly patients (>=75) pemetrexed ± bevacizumab: Randomized phase II in elderly patients found no PFS or OS benefit adding bevacizumab; response rate increased but with higher costs and hematologic toxicity.

    Fukuda et al.

    Pemetrexed + nintedanib in mesothelioma: Phase III LUME‑Meso did not meet its primary PFS end‑point; no confirmed benefit and increased certain adverse events (eg, neutropenia, pulmonary embolism).

    Scagliotti et al.

    Pemetrexed + radiotherapy for brain metastases: Small non‑randomized comparative study reported higher response and local control rates and improved short‑term survival for pemetrexed combined with stereotactic radiotherapy versus radiotherapy alone; validation in larger studies is needed.

    Zhang et al.

    TroVax + pemetrexed-cisplatin in MPM: Phase II single‑arm trial met immunologic primary end‑point with 95.6% immune response in per‑protocol analysis and acceptable safety; further phase III study warranted.

    Lester et al.

    Dosing prerequisites: Prior to initiating pemetrexed, initiate folic acid and vitamin B12 supplementation and administer corticosteroids the day before, day of, and day after pemetrexed; dose reductions or discontinuation may be required for toxicities from prior cycles.

    Prescribing information guidance

    Use of pemetrexed for squamous cell non-small cell lung cancer (squamous NSCLC) is explicitly excluded and will not be covered by the plan.

    Clinical compendia and guideline sources cited in the policy do not list pemetrexed as a recommended option for several tumor types; specifically, biliary tract cancer, head and neck cancers, hepatocellular carcinoma, and kidney cancer are not supported as standard indications in the referenced NCCN and UpToDate materials.

    Pemetrexed combined with carboplatin was shown to be inferior to etoposide-carboplatin in a randomized phase III trial for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) with worse overall survival, progression-free survival, and response rates; therefore pemetrexed-carboplatin is not supported as standard first-line therapy for ES-SCLC.

    The addition of nintedanib to pemetrexed‑cisplatin in unresectable epithelioid malignant pleural mesothelioma did not meet the phase‑III primary PFS end point (LUME‑Meso); no confirmed benefit was observed and higher rates of some adverse events were reported, so the combination is not supported.

    Within the provided source excerpts there are no additional explicit coverage exclusions beyond those already stated in the policy text.

    The policy considers pemetrexed experimental and investigational for multiple malignancies where effectiveness has not been established, including but not limited to acute leukemias, biliary cancer, breast cancer, colorectal cancer, pancreatic cancer, renal cell carcinoma, neuroendocrine tumors, and others listed in the policy.

    Testing for MTHFR polymorphisms to predict pemetrexed effectiveness or toxicity is considered experimental and investigational and is not supported by the policy (HCPCS code 81291 is listed as not covered for this purpose).

    Guideline and review sources cited in the policy do not support routine use of pemetrexed for biliary tract cancer, head and neck cancer, hepatocellular carcinoma, or kidney cancer; these indications are not listed as recommended therapeutic options in the referenced NCCN and UpToDate materials.

    For previously untreated extensive‑stage SCLC, pemetrexed‑carboplatin produced inferior outcomes (OS, PFS, and response rates) compared with etoposide‑carboplatin in randomized trials; consequently pemetrexed‑carboplatin is not supported in this setting.

    A Bayesian network meta-analysis and supporting reviews conclude that routine addition of bevacizumab to pemetrexed‑platinum regimens is not justified because no consistent efficacy or tolerability advantages were demonstrated for Pem‑Pt + B versus Pem‑Pt.

    In the excerpts provided there are no explicit statements labeled as 'not medically necessary' beyond the investigational/not‑recommended listings and exclusions already described elsewhere in the policy text.

    HCPCS codes not coveredHCPCSNot Covered
    81291MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C).
    ICD-10 codes not covered for indications listedICD-10Not Covered
    C15.3 - C15.9Malignant neoplasm of esophagus.
    C16.0 - C16.9Malignant neoplasm of stomach [gastric].
    C18.0 - C20Malignant neoplasm of colon, rectosigmoid junction, and rectum [colorectal].
    Creatinine clearance
    Creatinine clearance threshold>= 45 mL/min
    Source guidancePatients must have creatinine clearance >=45 mL/min for initial, maintenance, and recurrent pemetrexed dosing per prescribing recommendations
    Implication for dosingDo not initiate a new cycle if CrCl <45 mL/min; document calculated creatinine clearance prior to each cycle
    ANC (Absolute Neutrophil Count)
    Absolute neutrophil count (ANC) threshold>= 1500 cells/mm3
    Monitoring requirementObtain CBC including ANC prior to each cycle; document nadir and recovery as appropriate
    Cycle initiation implicationDo not begin a new cycle unless ANC >=1500 cells/mm3
    Platelet count
    Platelet count threshold>= 100,000 cells/mm3
    Monitoring requirementPerform platelet count prior to each cycle and document values in authorization record
    Cycle initiation implicationDo not begin a new cycle unless platelets >=100,000 cells/mm3
    Laboratory thresholds to start a new cycle
    Laboratory thresholds to start a new cycleANC >=1500 cells/mm3; Platelets >=100,000 cells/mm3; Creatinine clearance >=45 mL/min
    Documentation expectationCBC with ANC and platelet count plus calculated creatinine clearance should be documented prior to each cycle
    Action on failing thresholdsIf thresholds not met, delay cycle and consider dose modification per prescribing information
  1. Specify whether single-agent or combination therapy is requested
  2. Include prior therapy status and intent (first-line, subsequent-line)
  3. Provide dosing schedule and supportive supplementation plan
  4. Documentation Required

    Bevacizumab Add‑on Assessment

    If bevacizumab is being requested as an add-on to a pemetrexed‑platinum regimen, include rationale and supporting evidence; routine addition of bevacizumab to pemetrexed‑platinum is not routinely supported by the evidence and should be justified in the prior authorization documentation.

    • Provide clinical justification and references if requesting bevacizumab add‑on
    • Include pertinent real‑world outcomes or patient-specific factors (e.g., presence of brain metastases, hemoptysis, anticoagulation)
    Documentation Required

    Continuation of Therapy Requirements

    Continuation of therapy requires documentation that the member has not experienced unacceptable toxicity and that the disease has not progressed on the current pemetrexed regimen; dose reductions or discontinuation due to toxicity must be documented.

    • Document tumor response or stability and absence of progression
    • Provide records of toxicities and any dose modifications with rationale
    Documentation Required

    Baseline and Pre‑cycle Laboratory Thresholds

    Baseline and pre‑cycle laboratory thresholds must be documented in the medical record prior to each cycle: ANC ≥ 1500 cells/mm3, platelet count ≥ 100,000 cells/mm3, and creatinine clearance ≥ 45 mL/min. Periodic renal and hepatic chemistries and CBC monitoring (including nadir and recovery where available) should be provided.

    • Attach most recent CBC with differential and platelet count prior to dosing
    • Provide creatinine clearance (or serum creatinine and weight for calculation) and liver chemistries
    Documentation Required

    Supportive Care and Monitoring

    Supportive care and monitoring documentation is expected: initiation and continuation of folic acid (400–1000 mcg daily starting 7 days before first dose and continued through treatment and 21 days after last dose), intramuscular vitamin B12 (1000 mcg IM within the week before first dose and every 9 weeks thereafter), and corticosteroid prophylaxis (dexamethasone as indicated). Monitor CBC, renal and hepatic function per prescribing information.

    • Document initiation dates and ongoing supplementation schedule for folic acid and vitamin B12
    • Include corticosteroid prophylaxis plan (eg, dexamethasone schedule)
    • Provide recent laboratory monitoring results (CBC, chemistries)
    Documentation Required

    Documentation of Diagnosis and Performance Status

    Document histologic or cytologic confirmation of diagnosis, staging (eg, stage III/IV for NSCLC not amenable to curative therapy or mesothelioma stage), and ECOG performance status (preferably 0–2 where indicated). Include prior lines of chemotherapy and relevant prior treatment responses.

    • Attach pathology report confirming histology/cytology
    • Provide staging documentation and ECOG performance status assessment
    • Include prior treatment history and dates
    Note

    Reference Sources and Prescribing Information

    Reference the prescribing information and key clinical guidelines or literature when supporting requests: Alimta (Eli Lilly) and other pemetrexed prescribing information, Pemfexy and Pemrydi RTU labeling, NCCN guidelines, FDA approvals, and relevant trials/reviews (eg, Vogelzang 2003 mesothelioma trial; maintenance pemetrexed NSCLC studies). Include citations in the PA submission as appropriate.

    • Attach relevant prescribing information (Alimta, Pemfexy, Pemrydi RTU)
    • Cite NCCN guideline sections or pivotal trials used to justify therapy
    Note

    Other Provider Actions

    No additional provider actions specified in these source chunks beyond the documentation, prior authorization, monitoring, and supportive care items above.

    Salvage/PCNSL and re‑challenge: Pemetrexed has single‑agent activity in relapsed/refractory primary CNS lymphoma and has been used as re‑challenge therapy in peritoneal mesothelioma; consider higher doses and individualized dosing in PCNSL trials and re‑challenge where prior response and performance status permit.

    Evidence from small trials and case reports/series

    inv-65: first-line

    First-line NSCLC (cisplatin combo): Pemetrexed plus cisplatin is an approved first‑line option for locally advanced/metastatic non‑squamous NSCLC; dosing per labeling and histology‑specific benefit observed in trials.

    Phase III data support use in non‑squamous histology

    inv-66: second-line

    Second-line or maintenance: Single‑agent pemetrexed is a standard second‑line option for advanced NSCLC and is FDA‑approved for maintenance therapy after 4 cycles of platinum‑based first‑line chemotherapy in non‑squamous histology, with demonstrated PFS and OS benefit.

    FDA approval and randomized trial evidence

    inv-67: first-line

    Bevacizumab caution: Adding bevacizumab to pemetrexed‑platinum regimens lacks consistent RCT evidence of benefit; Bayesian NMA concluded Pem‑Pt + B showed no significant differences versus Pem‑Pt for key outcomes and routine addition is unjustified.

    Zhao et al.; Pem‑Pt + B not clearly superior

    IndicationRegimen / Dose & ScheduleCoverage stance
    Non-squamous non-small cell lung cancer (first-line, maintenance, or recurrent non-squamous disease)
    Pemetrexed 500 mg/m2 IV on Day 1 of each 21-day cycle; may be given as single agent or in combination with pembrolizumab and a platinum agent. Maintenance dosing continued until disease progression or unacceptable toxicity. Creatinine clearance ≥45 mL/min required.
    Covered with criteria
    IndicationRegimen / Dose & ScheduleCoverage stance
    Pleural or peritoneal mesothelioma (includes pleural mesothelioma as FDA‑approved indication)
    Pemetrexed 500 mg/m2 IV on Day 1 of each 21-day cycle in combination with cisplatin; continue until disease progression or unacceptable toxicity. (Pemrydi RTU administered undiluted over 10 minutes.)
    Covered with criteria
    IndicationRegimen / Dose & ScheduleSupportive measuresCoverage stance
    Malignant pleural mesothelioma (initial therapy)
    Pemetrexed 500 mg/m2 IV on Day 1 of each 21-day cycle + cisplatin 75 mg/m2 IV on Day 1; regimens administered every 21 days.
    Folic acid and vitamin B12 supplementation plus corticosteroid prophylaxis per prescribing information; dose reductions as needed for toxicity.
    Covered with criteria (FDA‑approved regimen)
    IndicationRegimen / Dose & ScheduleEvidence context / notesCoverage stance
    Malignant peritoneal mesothelioma (systemic therapy; first-line or re‑challenge)
    Pemetrexed with cisplatin (dose per mesothelioma regimens, e.g., pemetrexed 500 mg/m2 IV Day 1 + cisplatin 75 mg/m2 IV Day 1) or pemetrexed monotherapy in selected cases; use where performance status permits.
    Evidence from case reports and small series supports activity and re‑challenge in select patients; UpToDate notes pemetrexed+carboplatin may be preferred in palliative setting for less toxicity.
    Covered with criteria (limited evidence; patient selection required)
    IndicationRegimen / NoteCoverage stance
    Head and neck cancer — initial treatment for recurrent/metastatic disease
    Cisplatin + pemetrexed: UpToDate and NCCN do not recommend or list pemetrexed as an initial standard regimen for head and neck cancer; regimen not recommended as initial treatment.
    Not covered (not recommended)
    IndicationRegimen / DoseCoverage stance
    Locally-advanced or metastatic non-squamous NSCLC — first-line in combination with cisplatin
    Pemetrexed 500 mg/m2 IV on Day 1 + cisplatin 75 mg/m2 IV on Day 1 every 21 days.
    Covered with criteria
    IndicationRegimen / Dose & ScheduleSupportive measuresCoverage stance
    Maintenance therapy for non-squamous NSCLC after induction chemotherapy
    Pemetrexed 500 mg/m2 IV on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity (after 4 cycles of platinum-based first-line chemotherapy).
    Folic acid and vitamin B12 supplementation and corticosteroid prophylaxis per labeling; dosing per FDA-approved maintenance regimen.
    Covered with criteria
    IndicationRegimen / NoteCoverage stance
    Extensive-stage small-cell lung cancer (first-line)
    Pemetrexed-carboplatin has been studied (pemetrexed 500 mg/m2 IV Day 1 + carboplatin AUC 5) but was inferior to etoposide-carboplatin in phase III trials with worse OS and PFS.
    Not covered (not recommended / inferior regimen)
    IndicationRegimen / NoteCoverage stance
    Thymomas and thymic carcinomas — second-line systemic therapy
    Pemetrexed, with or without prednisone, per NCCN recommendations as a second‑line systemic therapy option.
    Covered with criteria (per NCCN guidance)
    IndicationRegimen / NoteEvidence / RationaleCoverage stance
    Advanced non-squamous NSCLC — carboplatin/pemetrexed with or without bevacizumab
    Carboplatin + pemetrexed ± bevacizumab (regimens vary; pemetrexed dosing commonly 500 mg/m2 IV Day 1 every 21 days).
    Real-world retrospective data show an OS association favoring addition of bevacizumab (median OS 12.1 vs 8.6 months; HR 0.80) but randomized trial/NMA evidence is inconclusive; clinical judgment required.
    Mixed / case-by-case coverage (clinical justification required)
    IndicationRegimen / NoteTrial resultCoverage stance
    Unresectable epithelioid malignant pleural mesothelioma — investigational combination
    Pemetrexed + cisplatin combined with nintedanib (nintedanib 200 mg twice daily on days 2–21 in trial) added to standard pemetrexed/cisplatin induction and maintenance in LUME-Meso.
    Phase-III LUME-Meso did not meet the primary PFS endpoint (no PFS benefit) and showed increased certain adverse events.
    Not covered / not supported (trial primary end-point not met)
    IndicationRegimen / Required supportive careDose modification guidanceCoverage stance
    Pemetrexed monotherapy or pemetrexed-containing chemotherapy across covered indications
    Pemetrexed 500 mg/m2 IV Day 1 every 21 days with mandatory folic acid and intramuscular vitamin B12 supplementation and corticosteroid prophylaxis per prescribing information.
    Dose reductions or discontinuation may be required based on toxicities from preceding cycle; follow prescribing information for adjustments.
    Covered with criteria (supplementation and monitoring required)
    Indication / Trial contextRegimens studied / examplesCoverage stance
    Various malignancies included in clinical trials and references cited
    Multiple pemetrexed-containing regimens studied in trials (examples: pemetrexed + cisplatin; pemetrexed + carboplatin; pemetrexed + carboplatin + bevacizumab; pemetrexed + cisplatin + nintedanib; maintenance pemetrexed), as referenced in the literature list.
    Informational / trial-based — coverage determined by specific indication and criteria
    Clinical implicationMTHFR polymorphism testing is considered investigational for predicting pemetrexed benefit; T allele may warrant closer hematologic monitoring
    EGFR mutation (exon 19 deletion, exon 21 L858R)
    EGFR exon-specific benefitSubgroup analyses show patients with EGFR exon 19 deletion or exon 21 L858R may benefit in PFS when pemetrexed-based chemotherapy is added to gefitinib
    Evidence sourcePooled analysis of randomized trials demonstrated improved PFS (EGFR exon 19: HR 0.50; exon 21 L858R: HR 0.46) with combination therapy
    Clinical considerationConsider combination gefitinib plus pemetrexed-based chemotherapy for selected patients with exon 19 or 21 sensitizing mutations based on multidisciplinary judgment
    Folic acid supplementation
    Folic acid 400-1000 mcg orally daily beginning 7 days before first dose and continued during therapy and for 21 days after last dose
    Vitamin B12 supplementationVitamin B12 1000 mcg IM during the week before the first dose and every 3 cycles thereafter; subsequent injections may be given the same day as pemetrexed
    Corticosteroid prophylaxisDexamethasone 4 mg PO twice daily for 3 days beginning the day before administration to reduce cutaneous reactions
    Pemetrexed mechanism (specific enzymes)
    Multi-targeted antifolate targetsInhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT)
    Pharmacologic effectInterrupts both purine and pyrimidine synthesis pathways contributing to antitumor activity
    Therapeutic implicationExplains observed activity in mesothelioma and non-squamous NSCLC and rationale for combination with platinum agents
    FDA‑approved dosing (mesothelioma)
    FDA‑approved mesothelioma dosing500 mg/m2 IV on Day 1 of each 21-day cycle with folic acid and vitamin B12 supplementation
    Administration noteInfuse over approximately 10 minutes and give cisplatin 75 mg/m2 beginning 30 minutes after pemetrexed when combined
    Supportive measuresCorticosteroid premedication and vitamin supplementation required to reduce toxicity
    Maintenance therapy
    Definition of maintenance therapyAdministration of pemetrexed after disease control (no progression) following 4 cycles of platinum-based first-line chemotherapy
    Dosing for maintenance500 mg/m2 IV on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity
    Eligibility criteriaHistologically/cytologically confirmed non-squamous NSCLC, ECOG PS 0-2, adequate organ function, and documented supplementation per labeling
    Candidate for pemetrexed (NSCLC)
    Candidate population (NSCLC)Patients with histologic or cytologic confirmation of stage III/IV non-squamous NSCLC not amenable to curative therapy
    Performance status and organ functionECOG PS 0-2 and adequate bone marrow, renal, and hepatic function required
    Use settingsFirst-line in combination with platinum chemotherapy and pembrolizumab (no EGFR/ALK aberrations), maintenance after platinum therapy, or recurrent/metastatic disease after prior chemotherapy
    LUME-Meso Trial
    LUME-Meso Trial designPhase-III randomized, double-blind trial of pemetrexed plus cisplatin with nintedanib versus placebo in unresectable epithelioid malignant pleural mesothelioma
    Enrollment458 patients randomized; primary end-point investigator-assessed PFS in the ITT population
    Outcome notePrimary PFS end-point was not met in the phase-III portion
    TroVax
    TroVax study contextPhase-II single-arm trial evaluating TroVax vaccine with pemetrexed-cisplatin in malignant pleural mesothelioma
    Immunologic primary end-pointPer-protocol analysis: 22/23 patients (95.6%) developed humoral or cellular immune response to 5T4
    Clinical outcomesDisease control observed in 87% (PR 17.4%, SD 69.6%); median PFS 6.8 months and median OS 10.9 months
    Pemetrexed (product names and uses)
    Product names and indicationsPemetrexed (antifolate) marketed as Alimta, Pemfexy, Pemrydi; used IV for malignant pleural mesothelioma and non-squamous NSCLC
    Administration routeIntravenous infusion (standard 500 mg/m2 dosing referenced)
    Supportive requirementsFolic acid, vitamin B12 supplementation and corticosteroid prophylaxis per prescribing information
    Salvage/regional uses: Pemetrexed has activity in relapsed/refractory PCNSL (higher doses studied) and has been used as re‑challenge systemic therapy in diffuse malignant peritoneal mesothelioma with reported disease control in case series; consider on a case‑by‑case basis with documentation of prior response and performance status.

    Evidence limited to small trials and case reports

    inv-65: first-line

    First-line cisplatin combination: Pemetrexed plus cisplatin is an approved first‑line option for locally advanced/metastatic non‑squamous NSCLC; dosing per labeling with histology‑specific benefit.

    Phase III data

    inv-66: second-line

    Second-line/maintenance: Single‑agent pemetrexed is an established second‑line therapy and is FDA‑approved as maintenance for non‑squamous NSCLC after 4 cycles of platinum‑based therapy with demonstrated improvements in PFS and OS in non‑squamous histology.

    FDA approval and pivotal trial evidence

    inv-67: first-line

    Bevacizumab add‑on assessment: Routine addition of bevacizumab to pemetrexed‑platinum regimens is not supported by NMA of RCTs; clinicians may consider bevacizumab addition based on individual patient factors and real‑world data but must document rationale and risks.

    Zhao et al.; Bagley real‑world findings require cautious interpretation